Key result
Adding ranolazine to amiodarone improves postoperative AF conversion over monotherapy, particularly in HFrEF.
Why the study?
Postoperative atrial fibrillation is a common complication after cardiac bypass surgery that requires termination, especially in patients with compromised left ventricular function, motivating an evaluation of the antiarrhythmic potency of amiodarone plus ranolazine versus amiodarone monotherapy in patients with HFrEF or HFpEF.
Does adding oral ranolazine to intravenous amiodarone improve the conversion rate and time to conversion of postoperative atrial fibrillation compared to amiodarone monotherapy in patients with HFrEF or HFpEF undergoing cardiac bypass surgery?
RCT (n=812)
randomly assigned to receive either A or A+R within each group
No
Does adding oral ranolazine to intravenous amiodarone improve the conversion rate and time to conversion of postoperative atrial fibrillation compared to amiodarone monotherapy in patients with HFrEF or HFpEF undergoing cardiac bypass surgery?
Answers are grounded in this paper and cite their sources.
This study investigates the addition of ranolazine to amiodarone for rapid conversion of post-CABG atrial fibrillation in patients stratified by HFrEF versus HFpEF, though quantitative outcome figures are truncated in the provided abstract text.
Postoperative atrial fibrillation (POAF) is a common complication in patients (pts) undergoing cardiac bypass surgery. In principle, there is no doupt that this arrhythmia should be terminated for several reasons, especially in pts with compromised left ventricular function. This summary compares the results of two separately evaluated single-center prospective studies executing during the last 4 years comprising patients with HFrEF (<40%) or HFpEF (>45%) and POAF. Investigated was the antiarrhythmic potency of amiodarone (A) as monotherapy vs. amiodarone+ranolazine (A+R) for converting POAF during a max. of 36-h period after initiation of treatment. Primary endpoints were conversion rate and time to conversion of arrhythmia in both groups. All pts were randomly assigned to receive either A or A+R within each group. In the HFrEF group 511 pts (446 M/65 F, 65±9 years) were enrolled and in the HFpEF group 301 pts (257 M/44 F, 66±10 years). From the HFrEF group, 255 pts were treated with i.v. A (loading dose 300 mg in 30 min + 1125 mg in 36 h) and 256 with A plus R (loading dose 500 mg p.o. + 375 mg after 6 h and then 375 mg twice daily); from the HFpEF group, 150 pts received only A while 151 the combined regimen at the same doses given for HFrEF pts.
No takes yet. Share an insight, caveat, or question.
Simopoulos et al. (2018) conducted an RCT in Postoperative atrial fibrillation (POAF) after cardiac bypass surgery in patients with HFrEF (<40%) or HFpEF (>45%) (n=812). Amiodarone plus ranolazine vs. Amiodarone monotherapy (i.v. loading dose 300 mg in 30 min + 1125 mg in 36 h) was evaluated on Conversion rate and time to conversion of postoperative atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: